AKEBIA THERAPEUTICS, INC.
Moat Score — Akebia Therapeutics, Inc.
Total Moat Score
12 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 4 / 5 | Akebia holds FDA approvals and patent protection for Vafseo and Auryxia, along with clinical and regulatory expertise built over years of kidney-disease-focused drug development, providing a real (if time-limited) legal and technical barrier to direct generic competition. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 1 / 5 | As a mid-cap specialty biopharma, Akebia does not have a manufacturing or R&D cost advantage versus larger competitors like Amgen or GSK. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 2 / 5 | Pricing is heavily constrained by the Medicare ESRD bundled-payment system and negotiations with concentrated large dialysis organizations, limiting the company's ability to set prices independently despite having differentiated products. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | Pharmaceutical products do not exhibit network effects; broader adoption by one prescriber or dialysis center does not directly increase the drug's value to another. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 3 / 5 | Once patients are stabilized on a particular anemia or phosphate-management regimen, nephrologists are often reluctant to switch therapies without clear clinical reason, creating moderate prescriber and patient inertia that favors incumbents. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 2 / 5 | The oral HIF-PHI anemia market is served by only Akebia and GSK in the U.S. following regulatory rejections of other candidates, suggesting the niche may be too specialized to support many more entrants, providing some efficient-scale protection. |